




CELL & GENE THERAPY INSIGHTS

SPOTLIGHT ON: Scale-up and scale-out – what do we really need and how will we get there?

Guest Editor: Jan Thirkettle, Transine Therapeutics



ThermoFisher
SCIENTIFIC

MILLIPORE
SIGMA

 **cytiva**

Lonza

SPONSORS:

COSPONSOR:

eppendorf

CONTENTS

SPOTLIGHT: Scale-up and scale-out: what do we really need and how will we get there?

LATEST ARTICLES

REPORT: Innovation Insights

Spotlight

Scale-up and scale-out: what do we really need and how will we get there?

FOREWORD

Scale-up and scale-out: what do we really need and how will we get there?

Jan Thirkettle

1131-1132

INNOVATOR INSIGHT

cGMP manufacturing made easy: a case study by ElevateBio

Michael Paglia & Shannon Eaker

1499-1512

INNOVATOR INSIGHT

Scaling-up the production of stem cell-derived extracellular vesicles in stirred-tank bioreactors

Aurélie Tacheny

1077-1083

EXPERT INSIGHT

Scalable downstream process development for *in vivo* gene therapy products: understanding full/empty separation capabilities and challenges with ion exchange chromatography

Kumar Dhanasekharan

1015-1021

EXPERT ROUNDTABLE

Evolution in AAV process development: 2022 and beyond

Alejandro Becerra, Matthias Hebben & Michael Mercaldi

1173-1182

INTERVIEW

Reaping the benefits in scalability: the flexibility of an in-house gene therapy manufacturing strategy

Alexandria Forbes

1107-1113

INTERVIEW

Industrializing viral vector manufacture

Daniel Teasley & Katherine Schewe

973-979

EXPERT ROUNDTABLE

Overcoming challenges in analytical assays for cellular therapies

Jara Joedicke, Eric Alonzo & Marsilius Mues

1195-1206

EDITORIAL

Improving the yield of rAAV manufacturing with HeLa producer cells lines to ensure patient access

Matthew Fuller

1127-1130

VIEWPOINT

From start-up to scale-up: a journey through AAV process development

Kevin Mouillesseaux

1115-1117

VIEWPOINT

Viral vector gene delivery: balancing safety, efficacy and dose

Thijs Gerritzen

1119-1123

Latest articles

INTERVIEW

Scaling up viral vector production: the importance of quality

Jeffrey Lacouchie

1087-1092

FASTFACTS

Cell and gene manufacturing: a case study approach to overcoming challenges – understanding the value of an expert supplier

Sean Werner & Adam Shields

1085

FASTFACTS

Getting closer to the *in vivo* environment with human AB serum

Trevor Smith

935

FASTFACTS

Adenovirus vector manufacturing platform using CIMmultus™ QA assures the supply of safe vaccines

Hana Jug

1125

INNOVATOR INSIGHT

Applying a closed, modular, semi-automated system to CAR T cell therapy manufacturing

Yongchang Ji

961-972

Report

Innovation Insights

INTERVIEW

Broadening horizons for extracellular vesicles as both therapeutic modality and delivery tool

Joana Correia

899-904

INTERVIEW

Evolving technology trends and regulatory pathways in the tissue engineered product space

William Fodor

891-897